Do I hear three? Number of process validation batches to be set by protocol
This article was originally published in The Gold Sheet
Executive Summary
FDA's upcoming process validation guidance will reflect a combination of traditional and QbD-like process design requirements, Joseph Famulare, deputy director of CDER's Office of Compliance, said at an Oct. 15 meeting sponsored by Pharmaconference and the University of Rhode Island College of Pharmacy in Bethesda, Md. He noted that the upcoming guidance has involved all parts of the centers for drugs, biologics and veterinary medicine and the Office of Regulatory Affairs. He further noted that "if you have a lot of knowledge management, this can be factored into the protocol. The protocol will be used to justify your batch number." Echoing the remarks of other FDA officials on the upcoming guidance, Doug Ellsworth, FDA's New Jersey District Director, said that "the Barr decision produced the three batches. Now everyone denies saying it. Three batches are gone. There is now a lifecycle approach to validation.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.